insulin analog

(redirected from Insulin analogues)

insulin analog

A synthetic insulin in which small changes in the amino acid structure of the polypeptide result in changes in the onset, peak effect, or duration of the molecule's physiological effects. Insulin aspart, glargine, and lispro are all insulin analogues.
See also: analogue
Medical Dictionary, © 2009 Farlex and Partners
References in periodicals archive ?
Five, long-acting insulin analogues should be considered to manage blood glucose in adults with type 1 or type 2 diabetes who have frequent, severe hypoglycemia with human insulin.
In addition, the same device will be used for insulin analogues (insulin glargine and insulin lispro), which are still under development.
Julphar launched its $150 million biopharmaceutical facility in 2012, which has the capacity to produce 1,500kg of recombinant human insulin and insulin analogues crystals (rDNA), equivalent to a combination of 30 million vials & 25 million cartridges & pens of insulin per year.
Under the collaboration, Beactica scientists have supported Sanofi with analysis of the interaction kinetics between insulin analogues and their two binding sites on the full-length insulin receptor.
Since the disease is not well controlled in many patients [2], as a response, new insulin analogues and different insulin treatment regimens were raised to cope with it [3].
has entered a worldwide collaboration with Sanofi to discover and develop novel, engineered insulin analogues. The collaboration leverages Thermalin's science, which alters the insulin molecule to achieve greater therapeutic performance.
Insulin analogues have been the subject of controversy relative to their therapeutic superiority and in relation to regular insulin and NPH.
Keywords: Diabetes, Hypoglycaemia, Insulin analogues, Levels of prevention, Modern glucose lowering drugs.
Human insulin analogues are extremely expensive therefore should seldom be used.
The advantages of insulin analogues (lower risk of hypoglycemia) are well-documented (5).
The effects of anti-insulin antibodies and cross-reactivity with human recombinant insulin analogues in the E170 insulin immunometric assay.